NASDAQ:HROW Harrow Health - HROW Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Harrow Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $20.80 +2.38 (+12.92%) (As of 03/27/2023 01:04 PM ET) Add Compare Share Share Today's Range$18.75▼$20.8050-Day Range$13.93▼$19.2452-Week Range$5.40▼$20.80Volume455,733 shsAverage Volume342,120 shsMarket Capitalization$563.06 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Harrow Health MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside13.5% Upside$23.00 Price TargetShort InterestBearish7.98% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth485.71%From $0.14 to $0.82 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector782nd out of 995 stocksPharmaceutical Preparations Industry383rd out of 482 stocks 2.5 Analyst's Opinion Consensus RatingHarrow Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.00, Harrow Health has a forecasted upside of 13.5% from its current price of $20.26.Amount of Analyst CoverageHarrow Health has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.98% of the outstanding shares of Harrow Health have been sold short.Short Interest Ratio / Days to CoverHarrow Health has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Harrow Health has recently increased by 32.52%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHarrow Health does not currently pay a dividend.Dividend GrowthHarrow Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HROW. Previous Next 2.6 News and Social Media Coverage News SentimentHarrow Health has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Harrow Health this week, compared to 1 article on an average week.Search InterestOnly 14 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows3 people have added Harrow Health to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow Health insiders have not sold or bought any company stock.Percentage Held by Insiders14.26% of the stock of Harrow Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.47% of the stock of Harrow Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Harrow Health are expected to grow by 485.71% in the coming year, from $0.14 to $0.82 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow Health is -38.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow Health is -38.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow Health has a P/B Ratio of 49.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Harrow Health (NASDAQ:HROW) StockHarrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter. Email Address HROW Stock News HeadlinesMarch 24, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and NeuroPace (NPCE)March 24, 2023 | markets.businessinsider.comB.Riley Financial Sticks to Its Buy Rating for Harrow Health (HROW)March 27, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 24, 2023 | finance.yahoo.comQ4 2022 Harrow Health Inc Earnings CallMarch 23, 2023 | finance.yahoo.comHarrow Announces Fourth Quarter and Year-End 2022 Financial ResultsMarch 22, 2023 | americanbankingnews.comHarrow Health (HROW) Scheduled to Post Earnings on ThursdayMarch 17, 2023 | benzinga.comROSEN, NATIONAL TRIAL COUNSEL, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWMMarch 14, 2023 | benzinga.comROSEN, A LEADING LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWMMarch 27, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 13, 2023 | benzinga.comHarrow Health Shareholder NoticeMarch 13, 2023 | finance.yahoo.comHarrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3%March 6, 2023 | benzinga.comROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWMMarch 6, 2023 | finance.yahoo.comHarrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and PharmacovigilanceMarch 2, 2023 | finance.yahoo.comHarrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023March 1, 2023 | morningstar.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of InvestorsFebruary 27, 2023 | benzinga.comHarrow Health, Inc.: Company Investigated by the Portnoy Law FirmFebruary 25, 2023 | seekingalpha.comBuy Harrow Health: Correcting A Shortsighted ViewFebruary 25, 2023 | benzinga.comINVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of InvestorsFebruary 25, 2023 | benzinga.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWMFebruary 24, 2023 | benzinga.comHarrow Health Investor AlertFebruary 24, 2023 | seekingalpha.comHarrow Health Has Done Very Well For Us In The Past Few Months, And We Expect MoreFebruary 24, 2023 | benzinga.comThe Law Offices of Frank R. Cruz Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of InvestorsFebruary 23, 2023 | benzinga.comHarrow Health Shareholder Action ReminderFebruary 23, 2023 | technews.tmcnet.comThe Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of InvestorsFebruary 22, 2023 | msn.comHarrow Health drops on new short report from Bonitas Research (update)February 16, 2023 | finance.yahoo.comIs Harrow Health (HROW) an Undervalued Stock?February 15, 2023 | finance.yahoo.comHarrow Launches Next-Generation Compounded Atropine FormulationsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow Health and its competitors with MarketBeat's FREE daily newsletter. Email Address HROW Company Calendar Last Earnings11/09/2021Today3/27/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HROW CUSIPN/A CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.00 High Stock Price Forecast$24.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+14.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E Ratio143.64 P/E GrowthN/ANet Income$-18,010,000.00 Net Margins-15.90% Pretax Margin-25.27% Return on Equity28.87% Return on Assets1.57% Debt Debt-to-Equity Ratio83.80 Current Ratio3.49 Quick Ratio3.20 Sales & Book Value Annual Sales$88.60 million Price / Sales6.14 Cash Flow$0.07 per share Price / Cash Flow292.26 Book Value$0.41 per share Price / Book49.05Miscellaneous Outstanding Shares27,070,000Free Float23,213,000Market Cap$544.38 million OptionableOptionable Beta0.17 Key ExecutivesMr. Mark L. Baum J.D. (Age 49)CEO & Chairman Comp: $1.07MMr. Andrew R. Boll C.F.A. (Age 40)C.M.A., CFA, CMA, CFO & Corp. Sec. Comp: $716.73kDr. Robert J. Kammer D.D.S. (Age 73)Special Advisor Comp: $91.88kMr. John P. Saharek MBA (Age 62)Chief Commercial Officer Comp: $621.92kJamie WebbDirector of Communications & Investor RelationsDr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyMr. Andrew LivingstonChief Innovation OfficerMs. Kim BarrattChief Talent OfficerMore ExecutivesKey CompetitorsEvolusNASDAQ:EOLSCogent BiosciencesNASDAQ:COGTJanux TherapeuticsNASDAQ:JANXArbutus BiopharmaNASDAQ:ABUSMersana TherapeuticsNASDAQ:MRSNView All CompetitorsInsiders & InstitutionsB. Riley Financial Inc.Bought 155,825 shares on 3/1/2023Ownership: 0.576%Northwestern Mutual Wealth Management Co.Bought 2,100 shares on 2/21/2023Ownership: 0.008%EAM Investors LLCBought 8,862 shares on 2/15/2023Ownership: 0.860%Morgan StanleyBought 18,365 shares on 2/15/2023Ownership: 0.111%Bamco Inc. NYBought 20,173 shares on 2/15/2023Ownership: 0.075%View All Insider TransactionsView All Institutional Transactions HROW Stock - Frequently Asked Questions Should I buy or sell Harrow Health stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harrow Health in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HROW shares. View HROW analyst ratings or view top-rated stocks. What is Harrow Health's stock price forecast for 2023? 1 brokers have issued 12-month price targets for Harrow Health's stock. Their HROW share price forecasts range from $22.00 to $24.00. On average, they predict the company's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 14.4% from the stock's current price. View analysts price targets for HROW or view top-rated stocks among Wall Street analysts. How have HROW shares performed in 2023? Harrow Health's stock was trading at $14.76 at the beginning of 2023. Since then, HROW shares have increased by 36.2% and is now trading at $20.11. View the best growth stocks for 2023 here. Are investors shorting Harrow Health? Harrow Health saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 2,160,000 shares, an increase of 32.5% from the February 28th total of 1,630,000 shares. Based on an average trading volume of 347,600 shares, the short-interest ratio is currently 6.2 days. View Harrow Health's Short Interest. When is Harrow Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our HROW earnings forecast. How were Harrow Health's earnings last quarter? Harrow Health, Inc. (NASDAQ:HROW) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.34. The company had revenue of $18.71 million for the quarter, compared to analyst estimates of $17.27 million. Harrow Health had a positive trailing twelve-month return on equity of 28.87% and a negative net margin of 15.90%. During the same period in the prior year, the business posted $0.32 earnings per share. What ETFs hold Harrow Health's stock? ETFs with the largest weight of Harrow Health (NASDAQ:HROW) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC), Invesco DWA SmallCap Momentum ETF (DWAS), Hartford Multifactor Small Cap ETF (ROSC) and Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB), What guidance has Harrow Health issued on next quarter's earnings? Harrow Health updated its FY 2023 earnings guidance on Monday, January, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $135.00 million-$143.00 million, compared to the consensus revenue estimate of $117.72 million. What other stocks do shareholders of Harrow Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Harrow Health investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), VBI Vaccines (VBIV), Exelixis (EXEL) and Mustang Bio (MBIO). What is Harrow Health's stock symbol? Harrow Health trades on the NASDAQ under the ticker symbol "HROW." Who are Harrow Health's major shareholders? Harrow Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (13.95%), Renaissance Technologies LLC (4.18%), Portolan Capital Management LLC (3.59%), Geode Capital Management LLC (0.90%), Acuitas Investments LLC (0.88%) and EAM Investors LLC (0.86%). Insiders that own company stock include Andrew R Boll, David P Kennedy, Horn R Lawrence Van, Mark L Baum, Opaleye Management Inc, Richard L Md Lindstrom and Richard L Md Lindstrom. View institutional ownership trends. How do I buy shares of Harrow Health? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Harrow Health's stock price today? One share of HROW stock can currently be purchased for approximately $20.11. How much money does Harrow Health make? Harrow Health (NASDAQ:HROW) has a market capitalization of $544.38 million and generates $88.60 million in revenue each year. The company earns $-18,010,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. How many employees does Harrow Health have? The company employs 182 workers across the globe. How can I contact Harrow Health? Harrow Health's mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The official website for the company is www.harrowinc.com. The company can be reached via phone at (615) 733-4730, via email at jwebb@harrowinc.com, or via fax at 858-345-1745. This page (NASDAQ:HROW) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.